Checkpoint Therapeutics Inc (CKPT) concluded trading on Wednesday at a closing price of $4.07, with 3.19 million shares of worth about $12.97 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 73.93% during that period and on Wednesday the price saw a gain of about 1.50%. Currently the company’s common shares owned by public are about 45.10M shares, out of which, 35.93M shares are available for trading.
Stock saw a price change of 2.26% in past 5 days and over the past one month there was a price change of 25.23%. Year-to-date (YTD), CKPT shares are showing a performance of 27.19% which increased to 111.98% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.38 but also hit the highest price of $4.50 during that period. The average intraday trading volume for Checkpoint Therapeutics Inc shares is 2.46 million. The stock is currently trading 25.36% above its 20-day simple moving average (SMA20), while that difference is up 26.68% for SMA50 and it goes to 42.38% higher than SMA200.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) currently have 45.10M outstanding shares and institutions hold larger chunk of about 22.64% of that.
The stock has a current market capitalization of $198.75M and its 3Y-monthly beta is at 1.22. It has posted earnings per share of -$1.44 in the same period. It has Quick Ratio of 0.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CKPT, volatility over the week remained 0.90% while standing at 4.93% over the month.
Stock’s fiscal year EPS is expected to rise by 72.34% while it is estimated to increase by 70.91% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by D. Boral Capital on January 13, 2025 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by B. Riley Securities stated Checkpoint Therapeutics Inc (CKPT) stock as a Buy in their note to investors on July 14, 2022, suggesting a price target of $7 for the stock. On June 09, 2021, B. Riley Securities Initiated their recommendations, while on January 20, 2021, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $16. Stock get a Buy rating from Lake Street on May 29, 2019.
